Jyong Biotech Ltd(US:MENS) Globenewswire·2025-12-04 13:30Core Viewpoint - Jyong Biotech Ltd. has entered into a non-binding Memorandum of Understanding (MOU) with a Vietnam-based pharmaceutical distribution company to explore the development and commercialization of MCS-2 in the Vietnamese pharmaceutical market [1][2]. Group 1: MOU Details - The MOU outlines that both parties will conduct due diligence and discussions to define the scope and structure of any potential collaboration, including commercial strategy, regulatory pathway, and local market execution [2]. - There is no guarantee that a definitive agreement will be reached or that the collaboration will be finalized [2]. Group 2: Strategic Importance - The CEO of Jyong Biotech emphasized that this MOU is a significant step in the company's Asia-focused strategy to introduce plant-derived MCS therapies to new markets, highlighting Vietnam's potential for patient access and local partnerships [3]. - This MOU follows a previously announced non-binding Letter of Intent with a South Korean pharmaceutical company to explore in-licensing and development opportunities for plant-derived MCS products [3]. Group 3: Product Status - MCS-2 is currently an investigational new drug candidate and has not yet received approval for commercial use in any jurisdiction [4]. Group 4: Company Overview - Jyong Biotech Ltd. is a science-driven biotechnology company based in Taiwan, focusing on developing and commercializing innovative plant-derived drugs, particularly for urinary system diseases, with initial market focus on the U.S., EU, and Asia [5]. - Since its establishment in 2002, the company has developed integrated capabilities across all key drug development functions, including early-stage drug discovery, clinical trials, regulatory affairs, manufacturing, and commercialization [5].